|
Lecanemab Update
Japanese drugmaker Eisai presented the results of its Phase 3 clinical trial (CLARITY AD) at the Clinical Trials on Alzheimer’s Disease (CTAD) conference last month. Eisai announced positive topline results from Clarity AD, a phase 3 study evaluating the safety and effectiveness of Lecanemab, an investigational anti-amyloid beta (Aβ) protofibril antibody for the treatment of mild cognitive impairment (MCI) due to AD and mild AD dementia (collectively known as early AD) with confirmed presence of amyloid pathology in the brain.
Lecanemab is being studied locally as part of the AHEAD prevention trial at Brigham & Women’s Hospital.
The AHEAD study is the first ever clinical trial to test the effect of Lecanemab (investigational antibody) in people who have no cognitive symptoms of Alzheimer’s disease (AD), but in whom biomarker tests indicate amyloid is present in the brain, known as “preclinical” AD. The AHEAD study is also the first AD trial to recruit people as young as 55 years old who are at risk of developing symptoms of AD as they get older. The AHEAD study will test whether the clinical effects reported in the Clarity AD clinically symptomatic population are similar in the AHEAD preclinical AD population.
For more information about the AHEAD study, visit: visit www.studymemory.org or call (617) 278-0600.
| 
